Mitomycin, ifosfamide, and cisplatin in non-small cell lung cancer.
Mitomycin, ifosfamide, and cisplatin have demonstrated the best single-agent activity thus far in patients with non-small cell lung cancer (NSCLC), the most common malignant disease in the western world. For this reason, we initiated a phase II study, giving these three agents in combination (designated MIC) to 74 patients with inoperable NSCLC. Sixty-six patients were evaluable for response, of whom 30 (45%) demonstrated a partial response and 7 (11%) a complete response. These results, along with those obtained in two other phase II trials of MIC in NSCLC, promoted us to begin a large-scale, multicenter, phase III study of MIC in patients with inoperable limited-stage NSCLC. In this ongoing study, patients have been randomized to receive treatment with MIC and radiotherapy or radiotherapy alone. We hope to resolve the issue of whether a survival advantage is conferred on NSCLC patients treated with radiotherapy in combination with this promising chemotherapeutic regimen.
Queen Elizabeth Hospital, Edgbaston, Birmingham, UK.
M H
MH
Cullen
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology; D002945:Cisplatin / Q000633:toxicity; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004334:Drug Administration Schedule; D005665:Furosemide / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007069:Ifosfamide / Q000633:toxicity; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy; D015080:Mesna / Q000008:administration & dosage / Q000627:therapeutic use; D008787:Metoclopramide / Q000008:administration & dosage / Q000627:therapeutic use; D016685:Mitomycin; D008937:Mitomycins / Q000633:toxicity; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D009367:Neoplasm Staging; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
D008937:Mitomycins; D016685:Mitomycin; D005665:Furosemide; D003907:Dexamethasone; D008787:Metoclopramide; D015080:Mesna; D002945:Cisplatin; D007069:Ifosfamide